Compare Abercrombie & Fitch Co. (ANF) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs BioNTech SE - ADR — how do they compare? Abercrombie & Fitch Co. trades at $113.1 (market cap $5.24B), while BioNTech SE - ADR trades at $93.17 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 4.4× Abercrombie & Fitch Co.'s market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ANF | BNTX | |
|---|---|---|
Market Cap | $5.24B | $23.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $119.34 |
52-Week Low | $65.61 | $83.89 |
Enterprise Value | $5.91B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $114.45, down 3.44% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong fundamentals with a P/E of 11.41, net income margin of 9.34%, and three consecutive quarterly EPS beats. Revenue grew to $4.95 billion in 2025, up from $4.3 billion in 2024, while operating cash flow reached $710.38 million. Recent news highlights institutional buying and an upcoming Q2 2026 earnings report on August 26, 2026.
Outlook is mixed: valuation metrics appear attractive, and earnings momentum supports upside, but overbought RSI levels and competitive retail headwinds pose risks. Analyst consensus is a $112.86 price target with 35.71% buy ratings, suggesting cautious optimism amid near-term volatility.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
